Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant-Reference-Cited by-同舟云学术

Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant

Published:2021-11-18 Issue:1 Volume:6 Page:
ISSN:2059-0105
Container-title:npj Vaccines
language:en
Short-container-title:npj Vaccines

Author:

Abhyankar Mayuresh M.,Mann Barbara J.^ORCID,Sturek Jeffrey M.^ORCID,Brovero Savannah,Moreau G. Brett,Sengar Anjali,Richardson Crystal M.,Agah Sayeh,Pomés Anna^ORCID,Kasson Peter M.^ORCID,Tomai Mark A.,Fox Christopher B.^ORCID,Petri William A.

Abstract

AbstractWe developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine.

Funder

1. University of Virginia Ivy Foundation Grant 2. University of Virginia’s Global Infectious Diseases Institute 3. Manning Fund

University of Virginia Global Infectious Diseases Institute University of Virginia Manning Fund

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Infectious Diseases,Pharmacology,Immunology

Link

https://www.nature.com/articles/s41541-021-00399-0.pdf

Reference30 articles.

1. Global Health Estimates: Life expectancy and leading causes of death and disability. https://www.who.int/data/maternal-newborn-child-adolescent-ageing/advisory-groups/gama/activities-of-gama.

2. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).

3. Chia, W. N. et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet.Microbe 2, e240–e249 (2021).

4. Manson, J. J. et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2, e594–e602 (2020).

5. Desai, N. et al. Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection. Nat. Commun. 11, 6319 (2020).

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview;Frontiers in Microbiology;2023-12-21

2. Biomedical equipments, vaccine and drug in the prevention, diagnosis and treatment of COVID-19;Heliyon;2023-07

3. The macrophage infectivity potentiator of Trypanosoma cruzi induces innate IFN-γ and TNF-α production by human neonatal and adult blood cells through TLR2/1 and TLR4;Frontiers in Immunology;2023-05-26

4. Role of toll‐like receptors in the pathogenesis of COVID‐19: Current and future perspectives;Scandinavian Journal of Immunology;2023-05-07

5. Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant;Vaccine;2023-04